SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

SCYX

Scynexis
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 18h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Watch for initiation of SCY-770 Phase 2 trial in Q4 2026 and any interim data in Q4 2027. Also monitor BARDA option exercises for SCY-247 funding. The cash runway into 2029 reduces near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

SCYX drug pipeline →

SCY-770

● Neutral Named in this press release
Impact
Phase
Phase 1 completed; Phase 2 ready
Time to market
Minimum 3-4 years, assuming positive Phase 2 data drives Phase 3 and potential accelerated approval via FDA-recognized surrogate endpoint (total kidney volume)
Next catalyst
None dated

What to watchWatch for the Phase 2 proof-of-concept study initiation in Q4 2026 (imminent) and, more importantly, the early efficacy readout on total kidney volume expected in the second half of 2027. SCY-770 must demonstrate a meaningful reduction in kidney growth versus placebo to justify the valuation implied by analyst targets (~$36 mean). Until then, the stock is driven by SCY-247 antifungal progress and the $214M BARDA contract, SCY-770 remains a high-risk/high-reward pipeline component.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$3.30
T+0 close · Nov 5, 2026 · via day close
Latest settled
+0.91%
T+5 · $3.33
Vs SPY
−2.38%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $3.30entry
  2. T+1 · 11d ago +6.06%α +5.75% · $3.50
  3. T+5 · 5d ago +0.91%α −2.38% · $3.33
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Scynexis reported Q3 2026 net loss of $8.5M ($0.71 per share) vs consensus EPS of -$0.72, a slight beat. Revenue was $0 (no license revenue) vs consensus of $87K, a miss. The company highlighted a BARDA contract worth up to $214M for SCY-247 and a Phase 2 start for SCY-770 in ADPKD in Q4 2026. Cash of $63.2M is expected to fund operations into 2029.

Key Financial Metrics

EPS
−$0.71
est −$0.72 · +1.4%
Revenue
$0.00
est $87.0K · -100.0% · -100.0% YoY
Rating
in line

Key Facts

  • Net loss per share of $0.71 vs consensus of -$0.72 (beat by 1.4%)
  • Revenue of $0 vs consensus of $87K (miss)
  • BARDA contract up to $214M non-dilutive funding for SCY-247, $18.5M in initial base period
  • Phase 1 of SCY-770 completed; Phase 2 in ADPKD expected to start Q4 2026
  • Phase 1 of IV SCY-247 completed; Phase 2 planned for 2027
  • Cash and investments $63.2M, expected to fund operations into 2029
  • New CFO and SVP of R&D appointed

Financial Impact

Net loss of $8.5M, cash burn of ~$7.9M from Q2 2026; BARDA contract provides up to $214M non-dilutive funding if all options exercised

revenuenet losscash

Risk Factors

  • No revenue from license agreements; company is pre-revenue
  • Phase 2 trial of SCY-770 may not meet endpoints
  • BARDA may not exercise all options, limiting funding
  • GSK relaunch of BREXAFEMME uncertain; milestone/royalty potential may not materialize
  • Stock price volatility typical for clinical-stage biotech

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396422

Track record

14 reports on SCYX

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
  2. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Viewing Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  4. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
  5. Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
  6. Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
  7. Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
  8. Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
  9. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
  10. May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026